Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography
- PMID: 27986209
- PMCID: PMC5175208
- DOI: 10.1016/j.semradonc.2016.08.002
Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography
Abstract
Prostate cancer rates vary substantially by race, ethnicity, and geography. These disparities can be explained by variation in access to screening and treatment, variation in exposure to prostate cancer risk factors, and variation in the underlying biology of prostate carcinogenesis (including genomic propensity of some groups to develop biologically aggressive disease). It is clear that access to screening and access to treatment are critical influencing factors of prostate cancer rates; yet, even among geographically diverse populations with similar access to care (eg, low- and medium-income countries), African descent men have higher prostate cancer rates and poorer prognosis. To date, the proportion of prostate cancer that can be explained by environmental exposures is small, and the effect of these factors across different racial, ethnic, or geographical populations is poorly understood. In contrast, prostate cancer has one of the highest heritabilities of all major cancers. Numerous genetic susceptibility markers have been identified from family-based studies, candidate gene association studies, and genome-wide association studies. Some prostate cancer loci, including the risk loci found at chromosome 8q24, have consistent effects in all groups studied to date. However, replication of many susceptibility loci across race, ethnicity, and geography remains limited, and additional studies in certain populations (particularly in men of African descent) are needed to better understand the underlying genetic basis of prostate cancer.
Copyright © 2016 Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Prostate Cancer Disparities by Race and Ethnicity: From Nucleotide to Neighborhood.Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):a030387. doi: 10.1101/cshperspect.a030387. Cold Spring Harb Perspect Med. 2018. PMID: 29229666 Free PMC article. Review.
-
Validation of genome-wide prostate cancer associations in men of African descent.Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):23-32. doi: 10.1158/1055-9965.EPI-10-0698. Epub 2010 Nov 11. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21071540 Free PMC article.
-
Generalizability of established prostate cancer risk variants in men of African ancestry.Int J Cancer. 2015 Mar 1;136(5):1210-7. doi: 10.1002/ijc.29066. Epub 2014 Jul 15. Int J Cancer. 2015. PMID: 25044450 Free PMC article.
-
Replication and heritability of prostate cancer risk variants: impact of population-specific factors.Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):938-43. doi: 10.1158/1055-9965.EPI-14-1372. Epub 2015 Mar 25. Cancer Epidemiol Biomarkers Prev. 2015. PMID: 25809866
-
Prostate cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology.J S C Med Assoc. 2006 Aug;102(7):241-9. J S C Med Assoc. 2006. PMID: 17319238 Review.
Cited by
-
The role of caveolin-1 and endothelial nitric oxide synthase polymorphisms in susceptibility to prostate cancer.Int J Exp Pathol. 2021 Dec;102(6):260-267. doi: 10.1111/iep.12394. Epub 2021 May 8. Int J Exp Pathol. 2021. PMID: 33964050 Free PMC article.
-
RNA-binding protein DND1 participates in migration, invasion, and EMT of prostate cancer cells by degrading CLIC4.Histol Histopathol. 2024 Oct;39(10):1343-1358. doi: 10.14670/HH-18-720. Epub 2024 Feb 9. Histol Histopathol. 2024. PMID: 38390782
-
Association of baseline self-reported fatigue with overall survival after stereotactic body radiation therapy for localized prostate cancer.Front Oncol. 2022 Dec 23;12:1015264. doi: 10.3389/fonc.2022.1015264. eCollection 2022. Front Oncol. 2022. PMID: 36620537 Free PMC article.
-
VPS53 Suppresses Malignant Properties in Colorectal Cancer by Inducing the Autophagy Signaling Pathway.Onco Targets Ther. 2020 Oct 21;13:10667-10675. doi: 10.2147/OTT.S254823. eCollection 2020. Onco Targets Ther. 2020. PMID: 33116643 Free PMC article.
-
LINC00908 Inactivates Wnt/β-Catenin Signaling Pathway to Inhibit Prostate Cancer Cell Stemness via Upregulating GSK3B and FBXW2.Cancer Med. 2025 May;14(9):e70887. doi: 10.1002/cam4.70887. Cancer Med. 2025. PMID: 40344383 Free PMC article.
References
-
- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer; Lyon: 2013. - PubMed
-
- SEER . Surveillance, Epidemiology, and End Results (SEER) Program. National Cancer Institute; - PubMed
-
- Howlader N,NA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK, editors. SEER Cancer Statistics Review, 1975-2008. In SEER Cancer Statistics Review, 1975-2008. National Cancer Institute; Bethesda, MD: 2011.
-
- Hsing AW, Yeboah E, Biritwum R, Tettey Y, De Marzo AM, Adjei A, Netto GJ, Yu K, Li Y, Chokkalingam AP, Chu LW, Chia D, Partin A, Thompson IM, Quraishi SM, Niwa S, Tarone R, Hoover RN. High prevalence of screen detected prostate cancer in West Africans: implications for racial disparity of prostate cancer. J Urol. 2014;192(3):730–5. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases